TORRENT PHARMA LTD
RESULTS
FOR Q4 & FY 14
TORRENT
PHARMA has released very good results for the 4th quarter and the
year ending March 2014.
Ø For
FY 13-14, revenues stood at Rs.4184 Cr, up by 30% from Rs.3212 Cr. In FY 12-13.
Ø EBITDA
for FY 13-14 stood at Rs.952 Cr up by 37% from Rs.693 Cr during same period
last year.
Ø PAT
for FY 13-14 stood atRs.664 Cr up by 53% compared to Rs.435 cr in FY 12-13.
Ø Dividend
is Rs.5 per share. Total Dividend is Rs.10 for the year. It is 30% of
consolidated Net Profits.
QUARTERLY
ANALYSIS
Ø Q4
REVENUES STAND AT Rs.1225 cr, up by 41% from Rs.871 cr in Q4 FY 13
Ø EBITDA
stands at Rs.350 Cr, up by 59% from Rs.220 Cr in Q4 FY 13.
Ø PBT
stands at Rs.317 Cr, up from Rs.159 cr , of Q4 FY 13 by 99%.
Ø PAT
stands at Rs.244 cr, up from Rs.11 Cr of Q4 FY 13, by 120%
Ø EPS
stands at Rs.14.4 against Rs.6.6 in Q4 FY 13, up by 119%.
Ø Domestic
formulations Business recorded revenues of Rs.256 Cr, up by 17%.
Ø International
Business revenues grew by 69% to Rs.887 Cr. Revenues from US operations grew by
335%. After currency adjustments, the growth is 282%.
Ø Revenue
from Europe grew by 19%.Brazil registered De-growth of 4%. Rest of Europe grew
by 16%.
The Company has proposed final
Equity Dividend of Rs.5 per Eq.Share, making the total dividend of Rs.10 , post
issue of Bonus shares in 1 : 1 ratio in July 13. The company has entered into a
definitive binding agreement with Elder Pharma to acquire its identified Branded formulations Business in India and
Nepal for Rs.2004 Cr. The process is going on in both companies.
BUSINESS INITIATIVES
During the year, company
acquired Indian Branded Formulations Business of Elder for a consideration of
Rs.2004 Cr. The transaction is expected to close by first Half of 2014.
CONSOLIDATED RESULTS TABLE
|
Torrent-consol
|
Q4FY14
|
Q3FY14
|
Q4FY13
|
Y FY14
|
Y FY 13
|
|
NET INCOME
|
1225
|
1015
|
871
|
4184
|
3212
|
|
total expenses
|
898
|
821
|
673
|
3319
|
2602
|
|
Profit from Opns
|
327
|
194
|
198
|
865
|
610
|
|
Net Profit
|
244
|
158
|
111
|
664
|
433
|
|
Dil.EPS
|
14.44
|
9.34
|
6.59
|
39.23
|
25.58
|
STANDALONE RESULTS TABLE
|
Torrent Pharma
|
Q4FY14
|
Q3FY14
|
Q4FY13
|
Y FY14
|
Y FY 13
|
|
NET INCOME
|
954
|
733
|
770
|
3365
|
2767
|
|
total expenses
|
636
|
581
|
541
|
2385
|
2160
|
|
Profit from Opns
|
318
|
152
|
229
|
980
|
607
|
|
Net Profit
|
252
|
114
|
153
|
762
|
546
|
|
Dil.EPS
|
14.89
|
6.74
|
9.04
|
45.05
|
32.29
|
* *
* E N D *
* *
No comments:
Post a Comment